

HAEMONETICS CORP  
Form 8-K  
June 08, 2006

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**  
**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported) June 7, 2006**

**HAEMONETICS CORPORATION**

---

*(Exact name of registrant as specified in its charter)*

**Massachusetts**

**1-10730**

**04-2882273**

---

*(State or other jurisdiction  
of incorporation)*

*(Commission  
File Number)*

*(I.R.S. Employer  
Identification No.)*

**400 Wood Road**

**02184**

---

*(Address of principal executive offices)*

*(Zip Code)*

**Registrant's telephone number, including area code 781-848-7100**

---

*(Former name or former address, if changed since last report.)*

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01**    **OTHER EVENTS**

On June 6, 2006 we entered into a definitive agreement with Arryx, Inc. (Arrix), a privately held nano-technology company, whereby we will acquire the outstanding shares of Arryx that we do not already own for \$26 million in cash. We have been collaborating with Arryx since October 2004 in developing and commercializing proprietary blood separation and processing technologies.

**Item 9.01**    **FINANCIAL STATEMENTS AND EXHIBITS**

(d)            *Exhibits.*

EXHIBIT 99.1      Press Release of Haemonetics Corporation dated June 8, 2006 announcing the acquisition of Arryx, Inc.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**HAEMONETICS CORPORATION**

---

(Registrant)

Date: June 8, 2006

**/s/ Ronald J. Ryan**

---

Ronald J. Ryan, Vice President and  
Chief Financial Officer